Dasatinib: a novel therapy for breast cancer?

Bibliography

• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609
   PubMed Web of Science ®Google Scholar
• Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 2009;101:38-47
   PubMedGoogle Scholar
• Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative' breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300
   PubMed Web of Science ®Google Scholar
• Varricchio L, Migliaccio A, Castoria G, et al. Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. Mol Cancer Res 2007;5:1213-21
   PubMed Web of Science ®Google Scholar
• Nautiyal J, Majumder P, Patel BB, et al. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 2009;283:143-51
   PubMed Web of Science ®Google Scholar
• Montero JC, Seoane S, Ocana A, et al. Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011;17:5546-52
   PubMed Web of Science ®Google Scholar
• Okamoto W, Okamoto I, Yoshida T, et al. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 2010;9:1188-97
   PubMedGoogle Scholar
• Nagaraj NS, Smith JJ, Revetta F, et al. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010;9:2322-32
   PubMed Web of Science ®Google Scholar
• Jallal H, Valentino ML, Chen G, et al. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 2007;67:1580-8
   PubMed Web of Science ®Google Scholar
• Corkery B, Crown J, Clynes M, et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 2009;20:862-7
   PubMed Web of Science ®Google Scholar
• Modi S, D'Andrea G, Norton L, et al. A Phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006;7:270-7
   PubMed Web of Science ®Google Scholar
• Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004;22:3080-90
   PubMed Web of Science ®Google Scholar
• Di Domenico M, Castoria G, Bilancio A, et al. Estradiol activation of human colon carcinoma derived Caco-2 cell growth. Cancer Res 1996;56:4516-21
   PubMed Web of Science ®Google Scholar
• Migliaccio A, Piccolo D, Castoria G, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998;17:2008-18
   PubMed Web of Science ®Google Scholar
• Guise TA, Yin JJ, Thomas RJ, et al. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 2002;30:670-6
   PubMed Web of Science ®Google Scholar
• Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78
   PubMed Web of Science ®Google Scholar
• Finn RS, Bengala C, Ibrahim N, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label Phase II study. Clin Cancer Res 2011;17:6905-13
   PubMed Web of Science ®Google Scholar
• Mayer EL, Baurain JF, Sparano J, et al. A Phase II trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011;17:6897-904
   PubMed Web of Science ®Google Scholar
• NCT00817531 Efficacy study of dasatinib in locally advanced triple-negative breast cancer patients. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 5 2013]
   Google Scholar
• NCT00780676 Personalized treatment selection for metastatic breast cancer. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 2013]
   Google Scholar
• NCT00546104 Phase II dasatinib study in advanced breast cancer. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 2013]
   Google Scholar
• Fornier MN, Morris PG, Abbruzzi A, et al. A Phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011;22:2575-81
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Tauer KW, Schnell FM, et al. Phase II trial of ixabepilone and dasatinib for treatment of metastatic breast cancer. Cancer Res 2012;72:abstract nr P5-20-08
   Google Scholar
• Somlo G, Atzori F, Strauss LC, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and preliminary efficacy in Phase I study CA180004. Clin Cancer Res 2013;19:1884-93
   PubMed Web of Science ®Google Scholar
• NCT01306942 Dasatinib in combination with trastuzumab and paclitaxel in the first line treatment of Her2-positive metastatic breast cancer patients. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 2013]
   Google Scholar
• Llombart A, Ravaioli A, Strauss L, et al. PD01-02: randomized Phase II study of dasatinib vs placebo in addition to exemestane in advanced ER/PR-positive breast cancer [BMS CA180-261 Study]. Cancer Res 2011;71(Suppl 3):PD01-02
   Google Scholar
• Wright GL, Blum J, Krekow LK, et al. PD01-01: randomized Phase II trial of fulvestrant with or without dasatinib in postmenopausal patients with hormone receptor-positive metastatic breast cancer previously treated with an aromatase inhibitor. Cancer Res 2011;71(Suppl 3):PD01-01
   Google Scholar
• NCT00696072 Randomized Phase II trial of letrozole with or without dasatinib as first and second-line treatment for hormone receptor-positive, Her2-negative post-menopausal breast cancer that is unresectable, locally recurrent or metastatic. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 2013]
   Google Scholar
• NCT00903006 Trial of fulvestrant, MK-0646, and dasatinib for metastatic hormone receptor-positive Her2-negative breast cancer. Available from: http://www.clinicaltrials.gov [Last accessed 5 February 2013]
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar